These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25764690)

  • 21. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
    Franco S; Tural C; Nevot M; Moltó J; Rockstroh JK; Clotet B; Martinez MA
    Gastroenterology; 2014 Sep; 147(3):599-601.e1. PubMed ID: 24859204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to hepatitis C virus protease inhibitors.
    Kieffer TL; George S
    Curr Opin Virol; 2014 Oct; 8():16-21. PubMed ID: 24852142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
    Zeuli JD; Adie SK; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asunaprevir for hepatitis C: a safety evaluation.
    Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
    Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.
    Pascu M; Martus P; Höhne M; Wiedenmann B; Hopf U; Schreier E; Berg T
    Gut; 2004 Sep; 53(9):1345-51. PubMed ID: 15306598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors.
    Lee WP; Tsai KC; Liao SX; Huang YH; Hou MC; Lan KH
    FEBS J; 2024 Mar; 291(6):1264-1274. PubMed ID: 38116713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.
    Raja R; Pareek A; Newar K; Dixit NM
    PLoS Pathog; 2019 Apr; 15(4):e1007701. PubMed ID: 30934020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
    Itakura J; Kurosaki M; Hasebe C; Osaki Y; Joko K; Yagisawa H; Sakita S; Okushin H; Satou T; Hisai H; Abe T; Tsuji K; Tamada T; Kobashi H; Mitsuda A; Ide Y; Ogawa C; Tsuruta S; Takaguchi K; Murakawa M; Asahina Y; Enomoto N; Izumi N
    PLoS One; 2016; 11(10):e0165339. PubMed ID: 27776192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4a.
    Saad KA; Eldawy MA; Elokely KM
    J Mol Model; 2022 Dec; 29(1):25. PubMed ID: 36580076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus.
    Lee WP; Lan KL; Liao SX; Huang YH; Hou MC; Lan KH
    Am J Chin Med; 2018; 46(4):835-852. PubMed ID: 29737209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
    Sagnelli E; Starace M; Minichini C; Pisaturo M; Macera M; Sagnelli C; Coppola N
    Infection; 2018 Dec; 46(6):761-783. PubMed ID: 30084057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus.
    Aghemo A; Colombo M
    Gastroenterology; 2013 Jul; 145(1):247-249. PubMed ID: 23726875
    [No Abstract]   [Full Text] [Related]  

  • 40. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay.
    Yoshimi S; Ochi H; Murakami E; Uchida T; Kan H; Akamatsu S; Hayes CN; Abe H; Miki D; Hiraga N; Imamura M; Aikata H; Chayama K
    PLoS One; 2015; 10(6):e0130022. PubMed ID: 26083687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.